Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats

E. Samnegård, U. T. Iwaniec, D. M. Cullen, D. B. Kimmel, Robert R. Recker

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The purpose of this cross-sectional study was to evaluate the effects of human parathyroid hormone(1-84) (hPTH) followed by maintenance treatment with 17β-estradiol (E2), risedronate (Ris), or a reduced dose of hPTH (LowPTH) on cortical bone in the ovariectomized (ovx) rat. Eight groups of ovx and one group of intact female rats (3.5 months) were left untreated for 11 weeks. For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 μg/kg per day on 3 days/week) and four groups received vehicle. Treatments were then changed to E2 (10 μg/kg per day on 2 days/week), Ris (3 μg/kg per day on 3 days/week), LowPTH (25 μg/kg per day on 3 days/week), or vehicle. Bone tissue was collected at weeks -11 (baseline), 0 (ovx effect), 12 (hPTH effect), 24, 36, and 48 (maintenance effect). Bone mineral density (BMD) and bone mineral content (BMC) of the diaphyseal femur and total cross-sectional area (Tt.Ar), marrow area (Ma.Ar), cortical area (Ct.Ar), and periosteal and endocortical bone formation of the tibia were measured. Ovariectomy resulted in lower BMD (weeks 0-48), unaffected BMC, and greater Tt.Ar (weeks 12 and 36), Ma.Ar (week 48), and Ct.Ar (weeks 0 and 12) compared with intact rats. Endocortical and periosteal bone formation were greater in the ovx than in the intact rats up to 23 weeks postovariectomy. Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls. In ovx rats pretreated with hPTH and then treated with Ris for 36 weeks, BMD and BMC were greater and Ma.Ar was smaller than in ovx controls. In ovx rats pretreated with hPTH and then treated with LowPTH, BMD, BMC, Ct.Ar, and endocortical bone formation were greater and Ma.Ar was smaller than in ovx controls. Treatment of hPTH-pretreated rats with E2 for 36 weeks did not affect cortical BMD, BMC, and Ct.Ar, although periosteal bone formation was lower in the E2 group compared with the ovx group. Thus, in ovariectomized rats, cortical bone gained by 12 weeks of hPTH treatment was maintained for up to 36 weeks by treatment with risedronate or low-dose hPTH, but not with 17β-estradiol.

Original languageEnglish
Pages (from-to)251-260
Number of pages10
JournalBone
Volume28
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Bone Density
Maintenance
Osteogenesis
Bone Marrow
Bone and Bones
human PTH protein
Cortical Bone
Estradiol
Ovariectomy
Subcutaneous Injections
Tibia
Femur
Therapeutics
Cross-Sectional Studies
Risedronate Sodium

All Science Journal Classification (ASJC) codes

  • Physiology
  • Hematology

Cite this

Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. / Samnegård, E.; Iwaniec, U. T.; Cullen, D. M.; Kimmel, D. B.; Recker, Robert R.

In: Bone, Vol. 28, No. 3, 2001, p. 251-260.

Research output: Contribution to journalArticle

Samnegård, E. ; Iwaniec, U. T. ; Cullen, D. M. ; Kimmel, D. B. ; Recker, Robert R. / Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. In: Bone. 2001 ; Vol. 28, No. 3. pp. 251-260.
@article{294468de31bf41ecb6313e4e5134083a,
title = "Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats",
abstract = "The purpose of this cross-sectional study was to evaluate the effects of human parathyroid hormone(1-84) (hPTH) followed by maintenance treatment with 17β-estradiol (E2), risedronate (Ris), or a reduced dose of hPTH (LowPTH) on cortical bone in the ovariectomized (ovx) rat. Eight groups of ovx and one group of intact female rats (3.5 months) were left untreated for 11 weeks. For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 μg/kg per day on 3 days/week) and four groups received vehicle. Treatments were then changed to E2 (10 μg/kg per day on 2 days/week), Ris (3 μg/kg per day on 3 days/week), LowPTH (25 μg/kg per day on 3 days/week), or vehicle. Bone tissue was collected at weeks -11 (baseline), 0 (ovx effect), 12 (hPTH effect), 24, 36, and 48 (maintenance effect). Bone mineral density (BMD) and bone mineral content (BMC) of the diaphyseal femur and total cross-sectional area (Tt.Ar), marrow area (Ma.Ar), cortical area (Ct.Ar), and periosteal and endocortical bone formation of the tibia were measured. Ovariectomy resulted in lower BMD (weeks 0-48), unaffected BMC, and greater Tt.Ar (weeks 12 and 36), Ma.Ar (week 48), and Ct.Ar (weeks 0 and 12) compared with intact rats. Endocortical and periosteal bone formation were greater in the ovx than in the intact rats up to 23 weeks postovariectomy. Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls. In ovx rats pretreated with hPTH and then treated with Ris for 36 weeks, BMD and BMC were greater and Ma.Ar was smaller than in ovx controls. In ovx rats pretreated with hPTH and then treated with LowPTH, BMD, BMC, Ct.Ar, and endocortical bone formation were greater and Ma.Ar was smaller than in ovx controls. Treatment of hPTH-pretreated rats with E2 for 36 weeks did not affect cortical BMD, BMC, and Ct.Ar, although periosteal bone formation was lower in the E2 group compared with the ovx group. Thus, in ovariectomized rats, cortical bone gained by 12 weeks of hPTH treatment was maintained for up to 36 weeks by treatment with risedronate or low-dose hPTH, but not with 17β-estradiol.",
author = "E. Samneg{\aa}rd and Iwaniec, {U. T.} and Cullen, {D. M.} and Kimmel, {D. B.} and Recker, {Robert R.}",
year = "2001",
doi = "10.1016/S8756-3282(00)00446-4",
language = "English",
volume = "28",
pages = "251--260",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats

AU - Samnegård, E.

AU - Iwaniec, U. T.

AU - Cullen, D. M.

AU - Kimmel, D. B.

AU - Recker, Robert R.

PY - 2001

Y1 - 2001

N2 - The purpose of this cross-sectional study was to evaluate the effects of human parathyroid hormone(1-84) (hPTH) followed by maintenance treatment with 17β-estradiol (E2), risedronate (Ris), or a reduced dose of hPTH (LowPTH) on cortical bone in the ovariectomized (ovx) rat. Eight groups of ovx and one group of intact female rats (3.5 months) were left untreated for 11 weeks. For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 μg/kg per day on 3 days/week) and four groups received vehicle. Treatments were then changed to E2 (10 μg/kg per day on 2 days/week), Ris (3 μg/kg per day on 3 days/week), LowPTH (25 μg/kg per day on 3 days/week), or vehicle. Bone tissue was collected at weeks -11 (baseline), 0 (ovx effect), 12 (hPTH effect), 24, 36, and 48 (maintenance effect). Bone mineral density (BMD) and bone mineral content (BMC) of the diaphyseal femur and total cross-sectional area (Tt.Ar), marrow area (Ma.Ar), cortical area (Ct.Ar), and periosteal and endocortical bone formation of the tibia were measured. Ovariectomy resulted in lower BMD (weeks 0-48), unaffected BMC, and greater Tt.Ar (weeks 12 and 36), Ma.Ar (week 48), and Ct.Ar (weeks 0 and 12) compared with intact rats. Endocortical and periosteal bone formation were greater in the ovx than in the intact rats up to 23 weeks postovariectomy. Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls. In ovx rats pretreated with hPTH and then treated with Ris for 36 weeks, BMD and BMC were greater and Ma.Ar was smaller than in ovx controls. In ovx rats pretreated with hPTH and then treated with LowPTH, BMD, BMC, Ct.Ar, and endocortical bone formation were greater and Ma.Ar was smaller than in ovx controls. Treatment of hPTH-pretreated rats with E2 for 36 weeks did not affect cortical BMD, BMC, and Ct.Ar, although periosteal bone formation was lower in the E2 group compared with the ovx group. Thus, in ovariectomized rats, cortical bone gained by 12 weeks of hPTH treatment was maintained for up to 36 weeks by treatment with risedronate or low-dose hPTH, but not with 17β-estradiol.

AB - The purpose of this cross-sectional study was to evaluate the effects of human parathyroid hormone(1-84) (hPTH) followed by maintenance treatment with 17β-estradiol (E2), risedronate (Ris), or a reduced dose of hPTH (LowPTH) on cortical bone in the ovariectomized (ovx) rat. Eight groups of ovx and one group of intact female rats (3.5 months) were left untreated for 11 weeks. For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 μg/kg per day on 3 days/week) and four groups received vehicle. Treatments were then changed to E2 (10 μg/kg per day on 2 days/week), Ris (3 μg/kg per day on 3 days/week), LowPTH (25 μg/kg per day on 3 days/week), or vehicle. Bone tissue was collected at weeks -11 (baseline), 0 (ovx effect), 12 (hPTH effect), 24, 36, and 48 (maintenance effect). Bone mineral density (BMD) and bone mineral content (BMC) of the diaphyseal femur and total cross-sectional area (Tt.Ar), marrow area (Ma.Ar), cortical area (Ct.Ar), and periosteal and endocortical bone formation of the tibia were measured. Ovariectomy resulted in lower BMD (weeks 0-48), unaffected BMC, and greater Tt.Ar (weeks 12 and 36), Ma.Ar (week 48), and Ct.Ar (weeks 0 and 12) compared with intact rats. Endocortical and periosteal bone formation were greater in the ovx than in the intact rats up to 23 weeks postovariectomy. Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls. In ovx rats pretreated with hPTH and then treated with Ris for 36 weeks, BMD and BMC were greater and Ma.Ar was smaller than in ovx controls. In ovx rats pretreated with hPTH and then treated with LowPTH, BMD, BMC, Ct.Ar, and endocortical bone formation were greater and Ma.Ar was smaller than in ovx controls. Treatment of hPTH-pretreated rats with E2 for 36 weeks did not affect cortical BMD, BMC, and Ct.Ar, although periosteal bone formation was lower in the E2 group compared with the ovx group. Thus, in ovariectomized rats, cortical bone gained by 12 weeks of hPTH treatment was maintained for up to 36 weeks by treatment with risedronate or low-dose hPTH, but not with 17β-estradiol.

UR - http://www.scopus.com/inward/record.url?scp=0035129745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035129745&partnerID=8YFLogxK

U2 - 10.1016/S8756-3282(00)00446-4

DO - 10.1016/S8756-3282(00)00446-4

M3 - Article

C2 - 11248654

AN - SCOPUS:0035129745

VL - 28

SP - 251

EP - 260

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -